digital currency central bank Top Featured

AI glasses ushered in the limelight, and Google reached a cooperation with domestic manufacturers. According to the news, on December 13, at the Android XR conference, Google reached a strategic cooperation with domestic consumer-grade AR glasses manufacturer XREAL to jointly build the Android XR ecosystem. According to media reports, OPPO, vivo, Huawei, Tencent and ByteDance are all evaluating the AI glasses project. In addition, a number of listed companies said on the investor question and answer platform that they have corresponding technology or product reserves in AI glasses. Huaxin Securities Research Report pointed out that AI glasses have become a new outlet in the smart wear market, or lead the next generation of terminal revolution. AI glasses not only have the effect of virtual vision enhancement, but also realize real-time analysis of user behavior and environment by integrating artificial intelligence algorithms, providing more accurate and personalized services. AI glasses also improve comfort and prolong wearing time in design and portability. At the same time, it provides a more natural and convenient interactive experience innovation through various sensing technologies. With the gradual reduction of costs, AI glasses are expected to be further widely used. According to the report of Wellsenn XR, it is estimated that after 2030, the AI+AR smart glasses industry will enter a period of rapid development; By 2035, AI+AR smart glasses will eventually replace traditional smart glasses, and the global sales of AI+AR smart glasses will reach 1.4 billion units, which is equivalent to the size of smart phones and will become the next generation general computing platform and terminal. (Securities Times)Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.

Jilin procuratorate prosecuted Jin Chunshan's suspected bribery case according to law. Recently, Jin Chunshan (deputy department level), the former party secretary and procurator-general of Yanbian People's Procuratorate of Jilin Province, was under the jurisdiction of Jilin Provincial People's Procuratorate, and the Liaoyuan People's Procuratorate filed a public prosecution with Liaoyuan Intermediate People's Court according to law. The case is being further processed. In the stage of examination and prosecution, the procuratorate informed the defendant Jin Chunshan of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of the defenders. The People's Procuratorate of Liaoyuan City sued the accusation that the defendant Jin Chunshan took advantage of his position as the county magistrate of Wangqing County, the deputy secretary and mayor of Hunchun Municipal Committee, and the party secretary and procurator-general of Yanbian People's Procuratorate to seek benefits for the relevant units and individuals in matters such as project contracting and work adjustment, and illegally accepted other people's property, with a huge amount. According to law, he should be investigated for criminal responsibility for accepting bribes.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.FTSE China A50 index futures fell 2%.

Extreme Yue will start two rounds of communication with Baidu and Geely, and the final employee compensation plan will be determined on December 17th. At 4: 30am on December 13th, Extreme Yue Xia Yiping said in the company's entire staff that after communicating with employee representatives, he agreed to the reasonable demands put forward by employees, and made a communication and promotion plan with Baidu and Geely, which will be completed from 13th to 17th. It is understood that the employees of Extreme Vietnam have listed a list of demands, including the requirement to pay five insurances, one gold and one tax for all employees from November to December, the N+1 compensation to be paid before December 31 this year, the settlement of on-the-job wages in December, etc. At the same time, it also involves pregnant women, after-care employees, employees with work-related injuries, employees who have settled down, front-line employees, employee owners, etc. (36Kr)The "hot" power of the ice and snow economy is infinite. The sales of ice and snow products in Yiwu are hot. With the new round of cold air coming, the cooling mode has been started again in many places across the country. The low temperature weather promotes the warming of ice and snow movement in many places, and the "heat" of ice and snow economy is booming. In Yiwu, Zhejiang, the sales of ice and snow products are hot. (Xinhua News Agency)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.